Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:CTXNYSE:HEXONASDAQ:VIRNYSEAMERICAN:ZOM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXCrescita TherapeuticsC$0.57+1.8%C$0.56C$0.41▼C$0.69C$10.49M1.6916,154 shs21,500 shsHEXOHEXO$0.71+2.5%$0.87$0.66▼$3.84$31.24M1.35880,508 shs305,500 shsVIRVir Biotechnology$6.12-2.7%$6.90$4.95▼$14.45$844.95M1.141.34 million shs876,317 shsZOMZomedica$0.12$0.09▼$0.20$95.35M1.034.85 million shs790,936 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXCrescita Therapeutics0.00%-3.39%-1.72%-1.72%+29.55%HEXOHEXO0.00%0.00%0.00%0.00%0.00%VIRVir Biotechnology+5.36%+14.36%-9.50%-40.83%-21.77%ZOMZomedica0.00%0.00%0.00%-21.31%-25.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTXCrescita TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHEXOHEXON/AN/AN/AN/AN/AN/AN/AN/AVIRVir Biotechnology2.7546 of 5 stars3.41.00.00.02.73.31.3ZOMZomedicaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTXCrescita Therapeutics 0.00N/AN/AN/AHEXOHEXO 0.00N/AN/AN/AVIRVir Biotechnology 2.86Moderate Buy$33.57448.55% UpsideZOMZomedica 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest CTX, HEXO, VIR, and ZOM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025VIRVir BiotechnologyThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $21.002/28/2025VIRVir BiotechnologyBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$26.00 ➝ $31.002/28/2025VIRVir BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$110.00 ➝ $110.002/27/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.001/31/2025VIRVir BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$110.00 ➝ $110.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTXCrescita TherapeuticsC$16.62M0.63C$0.48 per share1.20C$0.83 per share0.68HEXOHEXO$146.20M0.21N/AN/A$2.44 per share0.29VIRVir Biotechnology$63.71M13.26N/AN/A$11.82 per share0.52ZOMZomedica$25.19M0.00N/AN/A$0.24 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTXCrescita Therapeutics-C$2.61M-C$0.15N/A∞N/A-15.73%-15.60%-8.26%N/AHEXOHEXO-$845.90M-$5.21N/AN/AN/A-235.33%-74.04%-32.51%N/AVIRVir Biotechnology-$615.06M-$3.82N/AN/AN/A-678.40%-36.71%-31.00%5/1/2025 (Estimated)ZOMZomedica-$34.53M-$0.06N/AN/AN/A-232.88%-12.47%-11.84%N/ALatest CTX, HEXO, VIR, and ZOM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025VIRVir Biotechnology-$0.83N/AN/AN/A$8.59 millionN/A2/26/2025Q4 2024VIRVir Biotechnology-$0.85-$0.76+$0.09-$0.76$8.14 million$12.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTXCrescita TherapeuticsN/AN/AN/AN/AN/AHEXOHEXON/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/AZOMZomedicaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTXCrescita Therapeutics5.772.702.29HEXOHEXO0.010.410.24VIRVir BiotechnologyN/A8.948.94ZOMZomedicaN/A10.8210.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTXCrescita TherapeuticsN/AHEXOHEXO7.78%VIRVir Biotechnology65.32%ZOMZomedica8.95%Insider OwnershipCompanyInsider OwnershipCTXCrescita Therapeutics10.87%HEXOHEXO4.69%VIRVir Biotechnology15.60%ZOMZomedica4.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTXCrescita Therapeutics6218.41 millionN/ANot OptionableHEXOHEXO1,27744.00 million41.93 millionOptionableVIRVir Biotechnology580138.06 million116.24 millionOptionableZOMZomedica50979.95 million938.89 millionNot OptionableCTX, HEXO, VIR, and ZOM HeadlinesRecent News About These CompaniesTreat pet pain, inflammation, and anxiety with this high-tech at home therapyApril 24 at 3:19 AM | click2houston.comHelping Pets Live Pain-Free: High-Tech Treatments for Our Four-Legged Family MembersApril 11, 2025 | pix11.comIs Zomedica Corp. (ZOMDF) the Cheapest Stock Insiders Are Buying In March?March 28, 2025 | insidermonkey.com15 Cheapest Stocks Insiders Are Buying In MarchMarch 27, 2025 | insidermonkey.comEarnings call transcript: Zomedica Q4 2024 shows revenue growthMarch 15, 2025 | investing.comQ4 2024 Zomedica Corp Earnings CallMarch 15, 2025 | finance.yahoo.comZomedica Corp. (ZOMDF) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | seekingalpha.comZomedica (ZOMDF) Gets a Buy from Noble FinancialMarch 11, 2025 | markets.businessinsider.comZomedica Corp.March 8, 2025 | wsj.comZomedica Corp. Announces Transition to OTCQB Venture MarketMarch 4, 2025 | accessnewswire.comNYSE American to Commence Delisting Proceedings Against Zomedica Corp. (ZOM)March 4, 2025 | businesswire.comZomedica to Report Fourth Quarter and Full Year 2024 Financial Results with a Business Update on March 13th at 4:30 p.m. ETFebruary 26, 2025 | accessnewswire.comZomedica Corp.: Zomedica Improves Efficiency and Cuts Costs by Moving to New HeadquartersFebruary 12, 2025 | finanznachrichten.deZomedica Improves Efficiency and Cuts Costs by Moving to New HeadquartersFebruary 12, 2025 | accessnewswire.comZomedica Corp.: Zomedica Launches the TRUFORMA Enhanced Endogenous ACTH Assay to aid in Equine PPID DiagnosisFebruary 6, 2025 | finanznachrichten.deZomedica Launches the TRUFORMA(R) Enhanced Endogenous ACTH Assay to aid in Equine PPID DiagnosisFebruary 6, 2025 | accessnewswire.comZomedica Corp (ZOM) Stock Sees Market Value Hit $118.58 million: What Are the Implications?February 4, 2025 | bovnews.comZomedica Corp (ZOM) Stock Trading RecapJanuary 17, 2025 | bovnews.comZomedica Corp (ZOM) Stock’s -0.13% Decrease This Year: What’s the Story?January 13, 2025 | bovnews.comWhy Did Zomedica Corp (ZOM) Stock See 5.58% Surge in the Last 90 Days?January 10, 2025 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?CrowdStrike Stock is a Buy as Cyberthreat Environment ExpandsBy Chris Markoch | April 15, 2025View CrowdStrike Stock is a Buy as Cyberthreat Environment ExpandsMedtronic: A Dividend Aristocrat With Stability and InnovationBy Jeffrey Neal Johnson | April 22, 2025View Medtronic: A Dividend Aristocrat With Stability and Innovation3 Energy Stock Winners Even as Oil Prices PlungeBy Chris Markoch | April 11, 2025View 3 Energy Stock Winners Even as Oil Prices PlungeCoca-Cola Stock Looks Refreshing After the Relief Rally By Chris Markoch | April 13, 2025View Coca-Cola Stock Looks Refreshing After the Relief Rally CTX, HEXO, VIR, and ZOM Company DescriptionsCrescita Therapeutics TSE:CTXC$0.57 +0.01 (+1.79%) As of 04/24/2025 12:00 PM EasternCrescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue.HEXO NYSE:HEXOHEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc.Vir Biotechnology NASDAQ:VIR$6.12 -0.17 (-2.70%) Closing price 04:00 PM EasternExtended Trading$6.12 0.00 (0.00%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.Zomedica NYSEAMERICAN:ZOMZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
